TrialThe oncologist2024

Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.

Qing Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.